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The incidence of pancreatic cancer, the fourth leading cause of cancer death in United States, is
increasing worldwide. Even though the cure rate has doubled in 40 years, it is abysmally poor at
6–7%. As surgical resection remains the only curative treatment and less than 20% of the newly
diagnosed cancers are resectable, the major burden of disease management lies in early diag-
nosis, good prognostication, and proper neo-adjuvant and/or adjuvant therapy. With advancing
technologies and their ease of availability, researchers have better tools to understand pancre-
atic cancer. In the post-genetic era, proteomic, phosphoproteomic, metabolomic, and more have
brought us to a multi-omics era. These newer avenues bring promises of better screening mo-
dalities, less invasive diagnostics and monitoring, subtyping of pancreatic cancer, and fine tuning
the treatment modalities not only to the right stage of tumor but also to the right tumor biology.
As the multitudes of technologies are generating extensive amounts of incongruous data, they
are giving clinicians a lot of non-actionable information. In this paper, we wish to encompass the
newer technologies, sub-classifications, and future treatment modalities in personalized care of
patients with pancreatic cancer.
Keywords Molecular profiling, targeted therapy, pancreatic cancer
© 2016 Published by Elsevier Inc.
Introduction
The first connection between genetic inheritance and sus-
ceptibility to a disease was made in 1902 by Sir Archibald
Garrod for alkaptonuria. In 1956, the discovery of selective
toxicity for drugs primaquine on genetic basis was made. It
wasn’t until 2003 with the complete sequencing of the human
genome that more personalized and targeted therapies were
popularized. Tests are now moving beyond the gene into the
entire spectrum of molecular profiling, including the epigenomic,
transcriptomic, proteomic, and metabolomic profiling.
Pancreatic cancer, the fourth leading cause of cancer death
in the United States, is often diagnosed at a very late stage,
when curative treatments are no longer as good. The inci-
dence of this cancer is increasing worldwide as well as its rank
among cancer causing mortality. More than 80% of these
cancers are known to be locally advanced or metastatic at
the time of diagnosis. The only curative treatment remains to
be resection, but is only possible in less than 20% of patients.
Pancreatic duct adenocarcinoma, or PDAC, is the most
common form of pancreatic cancer. The causes and risk factors
of PDAC are largely unknown. The risk factors of tobacco,
obesity, exposure to chemicals, diabetes, chronic pancreati-
tis, and other conditions are up for debate.
Genetics
The fundamental essence in PDAC, like in all cancers, lies
in genetic mutations. The inherited genetic mutations are much
less common than sporadic mutations. Some genetic muta-
tions like mutations in p16 and TP53 genes can be found in
both inherited and sporadic occurrences. Others, such as
KRAS, BRAF, and DPC4 (Smad4), are usually found in spo-
radic PDAC. These genetic mutation signatures give each
PDAC a different prognosis and possibly different therapeu-
tic options. The p53 gene encodes for a nuclear phosphoprotein
which activates apoptosis. It is mutated in over 95% of pan-
creatic cancer cells. Loss of p53 has been proposed to be a
negative prognostic factor, even though no conclusive studies
have shown a correlation between p53 mutation and a poorer
clinical outcome (1). Germline mutation of p16 is a characteristic
Received July 14, 2016; accepted August 1, 2016.
* Corresponding author.
E-mail address: fhtresearch@gmail.com
ARTICLE IN PRESS
2210-7762/$ - see front matter © 2016 Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.cancergen.2016.08.001
Cancer Genetics ■■ (2016) ■■–■■
genetic alteration observed in over 80% of pancreatic cancer
cells. This locus encodes for suppressor genes. Multiple studies
have shown p16 expression as a positive prognostic factor
and any mutations as negative (2). In the Smad pathway, de-
letion or mutations of Smad4 have been reported in over 55%
of PDAC (3). The loss of Smad4 triggers the increase of cel-
lular proliferation and was associated with improved survival
after resection (4). In the Bcl-2 gene family, Bax gene has
been reported to promote apoptosis, whereas Bcl-2 seems
to inhibit it. The expression of Bcl-2 gene is remarkably cor-
related with a better survival. The mitochondrial pro-apoptotic
protein BNIP3, a member of the Bcl-2 family, plays a role in
hypoxia-induced apoptosis. Its expression is increased in
hypoxic regions of tumors and correlates with a worsened prog-
nosis (5,6).
Proteomics
Proteomics help identify the functional units of cellular pro-
cesses, proteins, and their intricate interaction networks and
signaling pathways. The advances of proteomic technolo-
gies, especially quantitative proteomics, have stimulated a great
interest in applying this technology for pancreatic cancer
studies.
PDAC has been well characterized at the genetic level;
however, these advances have failed to improve the under-
standing of disease progression and thus its clinical
management. The process as a whole—as we understand—
is a collection of multiple gene mutations causing activation
and inactivation of various cellular processes. Pharmaco-
logic targeting of genetic mutations has not been a viable option
in PDAC, because the common genes mutated in pancreat-
ic cancer are also the key regulators in normal cell expression.
It has become evident that genetic change alone is not suf-
ficient enough information to understand most PDAC. Thus,
proteomic based approaches have served to complement the
genomic data and provide critical information about the active
molecules driving PDAC. As such, it is believed that proteomic
based approaches are the next frontier. Harsha et al. made
a compendium of potential biomarkers of pancreatic cancer
(7). Identifying a novel biomarker opens avenues for earlier
diagnosis, targeted therapy, and monitoring of disease.
The most commonly used proteomic tools are two-
dimensional gel electrophoresis mass spectrometry (2D GE-
MS) and liquid chromatography mass spectrometry (LC-
MS). Improvements on gel-based techniques have been made
with better protein separation and quantification, but liquid chro-
matography (LC) is still currently the most-used technology
for protein separation prior to mass spectrometry analysis, as
it allows for the collection of both quantitative and structural
information at very high sensitivity (8). Multiple kits, like sub-
cellular fractionation, protein depletion, and post translational
modification are available commercially to increase the speci-
ficity and sensitivity of these tests.
By using a combination of the techniques, Theodoridis et al.
in 2012 identified over 3900 proteins in four pancreatic cancer
cell lines with 134 proteins significantly and differentially ex-
pressed between primary and metastatic cell populations (8).
Britton et al. identified 152 significantly different proteins among
2101 proteins, all between the tumor and non-tumor tissues
of 12 PDAC (9).
Quantitative proteomics has advanced with the use of
labeled techniques, such as stable isotope labeling by amino
acids in cell culture (SILAC), isotope-coded affinity tags (ICAT),
isobaric tags for relative and absolute quantitation, (iTRAQ)
and tandem mass tags (TMT). Using these techniques,
Kosanam et al. identified laminin gamma 2 (LAMC2) as a po-
tential PDAC biomarker (10).
On the other hand, quantitative label-free proteomics is
achieved through techniques like selected-reaction monitor-
ing (SRM) or multiple reactions monitoring (MRM). Using these
techniques, Ansari et al. considered it similar to protein deep-
mining and aggregated candidate biomarkers such as asporin,
CD9, CXC chemokine ligand 7, fibronectin 1, galectin-1,
gelsolin, intercellular adhesion molecule 1, insulin-like growth
factor binding protein 2, metalloproteinase inhibitor 1, stromal
cell derived factor 4, and transforming growth factor beta-
induced protein, among others (11).
Phosphoproteomics
Phosphorylation is a key event modulating protein activity,
therefore measuring protein phosphorylation is a useful
indicator of the activation status of a protein and of the gene
itself. In a study by Britton et al. (9), 12 PDAC tumor and
peritumoral pancreatic tissues were studied for proteomic and
phosphoproteomic data. Using techniques of Tandem Mass
Tag™ (TMT) Systems, liquid chromatography, tandem mass
spectrometry, immobilized metal affinity chromatography
(IMAC), and titanium dioxide (TiO2), Britton et al. found 2101
proteins and identified 6543 unique phosphopeptide se-
quences. Among those identified, 152 proteins and 635
phospho-peptides demonstrated a significant difference in
abundance between tumor and nontumor tissues. These
include the known and new up-regulated proteins in pancre-
atic cancer: Mucin-1, HIPK1, and MLCK. Among the phospho-
peptides that showed significant regulation, proteins involved
in cell migration (Rho guanine nucleotide exchange factors
& MRCKα) and formation of focal adhesions were identified.
Also found during the study were phosphorylation events that
indicate activation status of drug-targets like FYN, ERK2, AKT1,
RAF1, BRAF, GSK3a and others were found to be highly
modulated.
Genetic subtypes and prognosis
As technology has helped us to better understand pancreat-
ic adenocarcinoma, more literature has been able to discern
different sub-categories of PDAC. Although no classification
system is universally accepted, it is in a stage of evolution.
The first real classification was attempted in 2011 by Collisson
et al. (12), and has been improved by Moffitt et al. (13), and
more recently by Bailey (14).
Collisson et al. (12) have used Global gene-expression anal-
ysis on micro dissected PDAC tissues to subtype pancreatic
adenocarcinoma into classical, quasi-mesenchyma(QM), and
exocrine-like. They had 62 designated gene signatures. The
classical subtype had high expression of adhesion-associated
and epithelial genes. The QM subtype showed high expres-
sion of mesenchyme-associated genes. The exocrine-like
subtype showed relatively high expression of tumor cell-
derived digestive enzyme genes. Collisson et al. also followed
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the gene-signatures for clinical outcome and therapeutic re-
sponses. They found that the classical subtypes had longer
survival periods after resection than cancers of the QM type.
QM subtype cell-lines were also found to be more sensitive
to Gemcitabine than the classical subtype, while Erlotinib was
found to be more effective against the classical subtype. They
suggested that KRAS mutation status is an imperfect predic-
tor of sensitivity to EGFR-targeted therapy (12).
Moffitt et al. (13) used digital microdissection for tumor,
stromal, and normal gene expression. They identified and vali-
dated two tumor subtypes: classical and basal. The latter was
found to have a worse outcome in resected PDAC, with a
median survival time of 11 months compared to the 19 months
for classical subtype. They also found “normal” and “acti-
vated” stromal subtypes. Patients with PDAC, with activated
stromal subtype, had a worse median survival time of 15
months compared to 24 months for normal stromal subtype.
In multivariate Cox analysis, they found both classifications
to be independently and significantly associated with surviv-
al (stroma subtypes, P = 0.037; tumor subtypes, P = 0.003).
More recently Bailey et al. (14) identified 32 genes from
10 genetic pathways (KRAS, TGF-B, WNT, NOTCH, ROBO/
SLIT signaling, G1/S transition, SWI-SNF, chromatin
modification, DNA repair, RNA processing) that are consis-
tently mutated in pancreatic adenocarcinoma. Further
expression analysis of gene activity revealed four distinct sub-
types of PDAC: (1) squamous, (2) pancreatic progenitor, (3)
immunogenic, and (4) aberrantly differentiated endocrine exo-
crine (ADEX), that correlated with the histopathology of the
tumor. Squamous tumors were found to be enriched for TP53
and KDM6A mutations, up-regulation of theTP63N transcrip-
tional network, hypermethylation of pancreatic endodermal cell-
fate determining genes, and also have a poor prognosis.
Pancreatic progenitor tumors preferentially express genes in-
volved in early pancreatic development (FOXA2/3, PDX1 and
MNX1). ADEX tumors displayed up-regulation of genes that
regulate networks involved in KRAS activation, exocrine
(NR5A2 and RBPJL), and endocrine differentiation (NEUROD1
and NKX2-2). Immunogenic tumors contained up-regulated
immune networks including the pathways involved in B-cell
signaling pathways, antigen presentation, CD4+ T cell, CD8+
T cell and Toll-like receptor signaling pathways.
Treatment predictive markers in PDAC
i. Systemic chemotherapy for PDAC delivers a very low re-
sponse rate compared to other solid malignancies, and the
treatment has not drastically altered the longevity of pa-
tients diagnosed with pancreatic adenocarcinoma. Therapies
that improve on the status quo tend to cause debilitating
systemic toxicity. Therefore, there is a need to carefully
select therapy on the basis of specific prognostic factors
in order to allocate proper resources to realistic goals. The
predictive biomarkers hope to be helpful for selecting treat-
ments, in neoadjuvant, adjuvant, and palliative settings.
ii. Gemcitabine is a nucleoside pyrimidine analogue, which
has become the standard single agent treatment of PDAC,
as it was proven to improve clinical symptoms, quality of
life, and survival (15). Variability of key proteins in
gemcitabine transport and metabolism probably impact its
treatment response and toxicity. Gemcitabine needs the
presence of transporter mechanisms to enter cells. Two
processes of nucleoside transport have been identified,
hENT-1 being the major route for transporting gemcitabine.
It has been postulated that cells with lower hENT-1 ex-
pression have reduced intracellular penetration, and
therefore are relatively resistant. Studies have shown a pos-
itive correlation between hENT-1 gene expression and
chemosensitivity, as well as resistance with its pharma-
cologic inhibition. Increased hENT-1 expression has also
shown longer survival after Gemcitabine chemotherapy.
(16–19). There is a lot of data suggesting routine testing
for hENT-1 expression, and giving Gemcitabine to those
with high hENT-1 expression.
iii. FOLFIRINOX is a newer regimen for PDAC with a com-
bination of folinic acid, 5-fluorouracil (5-FU), irinotecan, and
oxaliplatin. Multiple preclinical and clinical trials have shown
efficacy of FOLFIRINOX over other therapies including
Gemcitabine. Unfortunately, the combination of irinotecan
and oxaliplatin comes with severe systemic toxicity and neu-
rotoxicity. Rarely is it given to our geriatric population. A
percentage of PDAC patients have defective DNA main-
tenance. This may predict chemosensitivity to platinum-
based therapy, and if proven, oxaliplatin may be used
preferentially (20).
iv. Nab-PACLITAXEL is a nanoparticle albumin-bound paclitaxel
with an average size of 130 nm. It was developed to pen-
etrate the thick stromal cells in the desmoplastic stromal
cells around PDAC, thereby increasing tumoral paclitaxel
concentration. It has been postulated that its uptake into
cells may be dependent on SPARC expression (21). The
role of SPARC in carcinogenesis is not well established,
as there are many conflicting reports. We do know that as
cells transform from PAN-INs to IPMN and finally to PDAC
they increasingly under express SPARC. Therefore, the in-
creased expression of SPARC would mean more efficacious
delivery of drug to the tumor but with resistance as it is
not taken up by the PDAC cells. SPARC expression has
not been proven to show any clinical significance yet, but
it is involved in numerous mechanisms in cancer (22). As
of now, its role is still underexplored.
Targeted therapy in PDAC
Apart from surgery and cytotoxic therapies for PDAC, actual
advances have been made in targeted therapies. Targeted
therapies are defined as drugs that target specific genes or
proteins, thereby preventing cancer from growing and spread-
ing. More than 40% of PDAC has such targets for which we
have or can design medications. Some of these targets are
as follows:
EGFR pathway inhibitors
EGFR is a transmembrane receptor member of the ErbB family
with a tyrosine kinase domain. It is involved in cell cycle reg-
ulation, cell survival, adhesion and differentiation. It is
overexpressed in up to 90% of pancreatic cancer samples.
Therefore, inhibitors targeting EGFR have been considered
as a promising therapeutic agent. Erlotinib is a tyrosine kinase
inhibitor which blocks downstream signal transduction. In a
large phase III trial of 569 patients with advanced pancreatic
cancer who received gemcitabine plus placebo or gemcitabine
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plus Erlotinib, the median survival length was increased in the
Erlotinib limb of the study (6.24 months versus 5.91 months,
P = .038) (23). Surprisingly, when EGFR or KRAS status was
analyzed in this subgroup, it was not shown to be predictive
of survival benefit. Erlotinib has been approved by the FDA
in combination with gemcitabine as a first-line treatment for
advanced PDAC. Cetuximab is a monoclonal antibody against
EGFR. After initial promise, it has not shown much survival
benefit when given with gemcitabine in advanced PDAC (24).
Facial rash was also a negative side effect of administered
Cetuximab, and an increase of the dose to achieve results
did not help. Gefitinib is a competitive inhibitor of ATP binding
to the intracellular kinase domain of EGFR. Of the 53 pa-
tients who were treated with gemcitabine and Gefitinib,
responses were seen in six, and stabilization of the disease
in twelve. The median progression free survival was 4.1 months
and median survival was 7.3 months, with a 1-year survival
rate of 27% (25).
HER2 is another ErbB family of transmembrane tyrosine
kinase receptors, which is overexpressed in 11% of pancre-
atic adenocarcinoma cases, correlating with poor survival (26).
Many studies have been done with HER2, but none has shown
significant improvement over standard chemotherapy, at least
for its inhibition with Trastuzumab in metastatic disease (27).
Another HER-2 inhibitor, Lapatinib, is being used in combi-
nation with Capecitabine with mixed to favorable results.
Nimotuzumab, another anti-EGFR monoclonal antibody, and
Afatinib, an inhibitor of EGFR, HER2 and HER4, are among
some newer drugs being evaluated (28).
KRAS pathway and secondary signaling inhibitors
The KRAS pathway and downstream signaling cascade in-
hibitors created mutations that are present in over 70% cases
of pancreatic cancer. It is a GTPase protein with oncogenic
activity, and gain-of-function mutations result in proliferation
and inhibition of apoptosis through the RAF/MEK/ERK and
PIK3/AKT pathways. It has no inhibitors in clinical practice at
present. Farnesylation is an important post-translational mod-
ification required for Ras activation. Farnesyl-transferase
inhibitors like Tipifarnib have failed to improve overall surviv-
al (29). Targets downstream of KRAS, such as the protein
kinase MEK, are being targeted by inhibitors like Selumetinib.
In a trial as a second-line therapy in combination with
Capecitabine, showed a minimal survival benefit (median
overall survival of 5.4 mo vs 5.0 mo) (30). Trametinib, another
MEK1/2 inhibitor, and Rigosertib, a first-in-class Ras mimetic
are few drugs that are being trialed.
IGFR pathway inhibitors
Insulin like growth-factor 1 receptor is also overexpressed in
pancreatic adenocarcinoma cells. Upon binding, there is ac-
tivation of several pathways involved in cell proliferation and
cell survival, such as the PIK3/AKT pathway. Monoclonal an-
tibodies like Cixutumumab and Ganitumab have been evaluated
in PDAC treatment, but failed to show a statically significant
survival benefit.
Angiogenesis pathway inhibitors
Neo-angiogenesis is essential for tumor progression and me-
tastasis. Vascular endothelial growth factor (VEGF) has been
is shown to overexpress in PDAC. VEGF inhibitors like
Bevacizumab have failed to improve overall survival in com-
bination with Gemcitabine in advanced pancreatic cancer.
Aflibercept, a recombinant fusion, binds VEGF-A, VEGF-B and
placental growth factors 1 and 2 thereby inhibiting VEGF-
ligand-dependent signaling processes, suppresses tumor
growth in pancreatic cell lines and xenografts. Sorafenib, an
oral multikinase inhibitor of Raf-kinase, VEGF-R2/-R3 and
PDGFR-β, Axitinib, an anti-angiogenesis and Necuparanib, a
re-engineered drug from Heparin with possible anti-tumor ac-
tivity, are being studied as well.
Embryonic pathway inhibitors
Hedgehog signaling has a critical role in cell proliferation.
Normal pancreatic cells silence this pathway, but pathologi-
cal activation is observed in PDAC. Sonic Hedgehog (SHH)
and other pathway proteins detected in precursor lesions and
tumors contribute to desmoplastic reaction (31). Genetically
engineered mouse models demonstrated a depletion of the
tumor matrix from SHH pathway inhibition, which could be a
promising strategy in pancreatic cancer therapy (32). Two
drugs being trialed are smoothened inhibitors Vismodegib
and Saridegib. Notch signaling is up-regulated in PDAC and
promotes tumorigenesis, and also proteolytic cleavages.
It regulates transcription of several genes involved in
proliferation and differentiation of cells, interacting with
other pathways such as Hedgehog, KRAS and NF-κB sig-
naling (33). RO4929097 and Demcizumab are also drugs being
trialed.
Poly ADP-Ribose Polymerase (PARP) inhibitors
Poly ADP-ribose polymerase (PARP) is a nuclear enzyme re-
cruited to repair cell DNA damage, and as recent evidence
showed, patients with defects in the homologous DNA re-
combination pathway may benefit from the use of PARP
inhibitors. Clinical trials testing those new agents like Olaparib
are ongoing (34,35). Mutations affecting BRCA genes promote
deficiency in DNA damage repair mechanisms, and may be
targeted by these agents.
mTOR and PI3K/Akt pathway inhibitors
RAS phosphorylates PI3K, thus activating Akt, a serine/
threonine kinase. Signal transduction by activated PI3K/Akt
plays a role in tumor cell proliferation, survival, and metabo-
lism, usually through several downstream targets, including
the mammalian target of rapamycin (mTOR). BKM120 (a PI3K
inhibitor), RX-0201 (an Akt antisense oligonucleotides), BEZ235
(a combined inhibitor of PI3K and mTOR), and everolimus (an
oral mTOR inhibitor) are all being trialed.
Tumor stroma inhibitors
The stroma is a critical compartment of PDAC formation, pro-
gression, metastasis, and resistance to therapy. Targeting the
stromal micro-environment is a strategy being studied.
PEGPH20, a PEGylated formulation of recombinant Hyal-
uronidase in Nab-Paclitaxel and Gemcitabine, is being studied.
Inhibition of PDGFR with Gleevec and TKI258 is being tested.
Matrix metalloproteinase inhibitors such as Marimastat are also
an option.
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Test samples
Blood
Tumor marker: CA19-9
CA19-9 is a sialylated Lewis (a) antigen, which is an epitope
produced by epithelial cells. It is present on the surface of eryth-
rocytes and in mucin secreted by pancreatic cancer cells. Lewis
(a) antigen is formed after fucosylation with the Le enzyme, while
the Lewis (b) antigen is formed by both the Le and Se enzymes.
Humans who do not have a functional Le enzyme (le-/le- geno-
type), approximately 5–10% of the population, do not produce
detectable CA19-9 (36). False elevations of CA19-9 are com-
monly encountered in patients with benign pancreatobiliary
conditions like pancreatitis and biliary obstruction (37). It is not
recommended for routine screening of PDAC as specificity of
the test and prevalence in PDAC is low (38).
CA19-9 has a significant value as a prognostic factor. It
has been used as a predictor of unresectability—especially
in the absence of pancreatitis or biliary obstruction (39). It can
also be used post-operatively to prognosticate survival. Berger
et al. (40) demonstrated that patients with CA 19-9 ≥ 90 U/
mL after resection had a significantly worse overall survival.
In that study, patients with CA 19-9 < 90 U/mL, had a median
survival of 21 months compared to 10 months for patients with
CA 19-9 ≥ 90 U/mL. A rising CA19-9 in a known patient with
PDAC suggests progression—prompting further investigation—
and when confirmed with other radiographic data, could be
used clinically to alter management protocol.
Circulating tumor cells
A major cause of pancreatic cancer mortality is tumor metas-
tasis, prompting a search for biomarkers for cancer diagnosis,
staging, prognosis and therapeutic monitoring. Thomas Ashworth
in 1869 first reported tumor cells circulating in the blood of cancer
patients. These Circulating Tumor Cells (CTCs) are becom-
ing widely recognized as one of these novel biomarkers. These
cells have acquired the ability to invade and disseminate in the
circulatory system. It is hypothesized that the presence of CTCs
in blood correlates with advanced disease and metastasis, with
varying degrees of evidence in other solid cancers like breast,
colorectal, and prostate cancer.
CTCs are usually very rare—in the range of one CTC per
10 million leukocytes (41). Pancreatic cancer patients are re-
ported to show one of the lowest CTC levels among cancer
patients (42). All tests usually include a two-step process: en-
richment and detection. The enrichment portion is usually done
using density gradient centrifugation. Some labs use varied
techniques like membrane filtration, buoyant density, and also
tetrameric antibody complex that increase the specific cell’s
density. For more specific enrichment immunological capture
techniques have been developed. For detection of meta-
static malignancies, epithelial-specific proteins have been
employed for positive selection of CTCs. The epithelial cell
adhesion molecule (EpCAM) is the most frequently used
antigen for this application. This concept has been devel-
oped into immunomagnetic bead separation systems and is
commercially available in magnetic-activated cell sorting
systems (Miltenyi Biotec GmbH), EasySep cell separation
(StemCell Technologies), cell isolation by Dynabeads
(Invitrogen), and the Cell-Search system (Veridex) (43).
CellSearch™ CTC test (Veridex, Raritan, NJ) is the first
FDA cleared test for capturing and enumerating CTCs. Their
kit is intended for the enumeration of CTCs of epithelial origin
(CD45−, EpCAM+, and cytokeratins 8, 18+ , and/or 19+) in
whole blood. It has been approved as a prognostic test in
breast, colorectal, and prostate cancers.
CellSearch and other labs have been used to detect CTCs
in pancreatic cancer as well. Among the 16 patients studied
by Allard et al. (42) with metastatic pancreatic cancer, six
(37.5%) had CTCs in their blood. Bidard et al. (44) in 2013
presented a case series of 79 patients with locally advanced
pancreatic cancer and showed detection of one or more CTCs
per 7.5 ml of blood in 5% of patients at onset, and 9% of pa-
tients after two months of chemotherapy. CTC positivity was
associated with poor tumor differentiation (P = 0.04), and with
shorter overall survival in multivariable analysis (RR = 2.5,
P = 0.01). In a meta-analysis by Han et al. (45) that included
nine studies with 268 CTC-positive markers among 623 PDAC
patients, there was a significantly worse overall survival and
progress-free survival than those in the CTC-negative group.
In a study by Ren et al. (46) in 2011 of 41 patients with
advanced PDAC, CTCs were detected in 33 (80.5%) pa-
tients before any therapy. This number decreased to 12 (29.3%)
patients a week after the first cycle of 5-fluorouracil chemo-
therapy. Apoptotic CTCs were also detected after the cycle
of chemotherapy, thus showing that detection of CTCs may
be able to validate the efficacy of chemotherapy.
Cell-free DNA (cfDNA)
Advanced-stage tumors often shed DNA into the blood-
stream, which can be isolated from a serum from peripheral
blood draws. They can be detected by polymerase chain re-
action (PCR) or next-generation sequencing (NGS) based
testing. Cell-free DNA testing could make tissue biopsy un-
necessary and thus reduce complications, delays, and costs
associated with invasive tissue biopsy in PDAC patients. This
technique also has a potential benefit of being able to seri-
ally monitor the quantity and identities of genetic matter over
time by peripheral blood draws. This technique could help
monitor therapy response and relapse.
cfDNA is more abundant in PDAC than healthy controls.
More than 75% of metastatic PDAs have tumor-derived cfDNA
detectable by PCR-based single-gene methods (47). The con-
cordance between mutations observed in the primary or
metastatic PDAC tumor tissue and the cfDNA has yet to be
established. In a recent study by Zill et al. (48) they ana-
lyzed 54 genes in tumors for cfDNA, and 26 patients suggested
that cfDNA sequencing should be considered in pancreatic-
biliary cancer trials where tissue sampling is unsafe, infeasible,
or otherwise unsuccessful. The sequencing failed in nine pa-
tients (35%) but in the remaining 17, 90.3% (95% CI: 73.1–
97.5%) of mutations detected in tumor biopsies were also
detected in cfDNA, giving knowledge of tumor genotype or
the abundance of circulating tumor DNA. Many more such
studies are being designed as “Liquid biopsies” and are avail-
able commercially.
Urine
Metabolites of pancreatic cancer are excreted in urine. Many
have found multiple microRNAs (miRNA) to discriminate
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between resectable and non-resectable pancreatic cancer, and
benign pathology. Debernardi et al. showed significant
overexpression for a subset of miRNAs (miR-143, miR-223,
miR-30e) to differentiate between PDAC Stage I versus healthy
individuals, and another a subset of miRNAs (miR-204, miR-
143, miR-223) to differentiate between Stage I and Stages
II–IV PDAC (49). Schonemeier et al., using immunoassay and
IHC testing, did urine proteome analysis and found that it out-
performed CA 19-9 by a 15% increase in sensitivity. They found
that Fetuin-A was the most prominent peptide marker for PDAC
(50). Radon et al. identified LYVE-1, REG1A, and TFF1 as
protein biomarkers to detect patients with early-stage pan-
creatic cancer via SDS-PAGE-Liquid Chromatography-
Tandem Mass Spectrometry with eighteen urine samples from
healthy patients with chronic pancreatitis and patients with
PDAC (51).
Feces
Cologuard® (Exact Sciences Corporation, Madison, WI, USA)
is an FDA approved multitarget stool DNA test in CRC screen-
ing (52). It includes assays for aberrantly methylated BMP3
and NDRG4 genes, mutant KRAS and β-actin, as well as an
immunochemical assay for human hemoglobin. The test
showed a sensitivity of 92% with the DNA testing (53). The
process includes sending the stool sample where laboratory-
based processing entails amplification and detection with the
use of Quantitative Allele-specific Real-time Target and Signal
Amplification (QuARTS™) technology (54). The results of
assays are given a composite score which is used to deter-
mine a positive or negative result. If positive, the patient is
to proceed with a colonoscopy.
This principle has been used by Kisiel et al. They pub-
lished their data in 2012 with 90% specificity, methylated BMP3
detected 51% of PDACs, mutant KRAS detected 50%, and
combination detected 67%. This study demonstrates that stool
assay of a methylated BMP3 and mutant KRAS can detect
PDAC (55). Its feasibility is being studied by Chung et al.
ClinicalTrials.gov Identifier: NCT01104129 (56).
Microbiome
Our understanding of the biological mechanisms leading to
carcinogens has been evolving, and the concept of parasitic
origin of cancer is an older concept. With advancing technol-
ogy, we have shed greater light in this field. This parasitic effect
is probably because of the immunological response to such
infections, most often bacterial or viral (57). Many cancer in-
ducing viruses have been documented, including Hepatitis C,
Human Papilloma Virus, and the Human Immunodeficiency
Virus. They either interfere at the genetic level or affect the
cells immunologically. Two bacteria, Porphyromonas gingivalis
in the oral flora and Helicobacter pylori in the gastric flora, have
been studied extensively in pancreatic cancer.
P. gingivalis has been stated to cause periodontal disease,
and periodontal disease has been linked with pancreatic cancer,
meaning P. gingivalis may have some causality to pancreat-
ic cancer (58). In some studies, a 4-fold increase in risk of
pancreatic cancer was seen in people with severe periodon-
titis (59). This could be because of the direct effects of
inflammation, but immunomodulatory effects of P. gingivalis
is also postulated (59). Its diagnosis with culture and anti-
body testing may be helpful in screening for high risk patients.
H. pylori’s epidemiological relationship with gastric cancer
has been well studied. Its association with pancreatic cancer
has been hypothesized, but in the few studies of the last few
decades, no consistent relationship has been shown.
Saliva
Similar to stool testing, testing saliva is a non-invasive pro-
cedure. Apart from detecting P. gingivalis, which was discussed
in the previous section, it has been postulated that metabo-
lites of the pancreatic cancer itself might be identified in the
saliva. Many circulatory molecules are present in saliva, which
can be discriminatory for diseases including cancer screen-
ing and detection. Many studies have reported that salivary
constituents can distinguish between oral diseases and sys-
temic diseases (lung cancer, breast cancer, pancreatic cancer,
and ovarian cancer). RNAs, both coding RNAs (mRNAs) and
noncoding RNAs (ncRNAs), have been studied extensively.
ncRNAs have recently been interesting for researchers as their
short size makes them more stable and less susceptible to
degradation as compared to RNAs. Their diverse roles in phys-
iology and cancer biology are being studied extensively. RNAs,
metabolites, and other biochemical compounds are being re-
viewed for translational clinical application and may have huge
implications with regard to both costs and benefits for pan-
creatic cancer care.
mRNA
Zhang et al. identified 12 messenger RNA biomarkers to di-
agnose pancreatic cancer, of which 4 mRNAs identified are
discriminatory for the detection of resectable and borderline
resectable pancreatic cancer with high sensitivity and speci-
ficity (60). The logistic regression model with the combination
of the 4 mRNA biomarkers (KRAS, MBD3L2, ACRV1, and
DPM1) could differentiate pancreatic cancer patients from un-
affected patients.
miRNA
MicroRNAs have been reported to be aberrantly expressed
in patients with pancreatic cancer (61). Many salivary miRNAs
have been studied. According to one study, miR-3679-5p and
miR-940 had discriminatory power to detect resectable pan-
creatic cancer with sensitivities of 62.5–72.5% and specificities
of 70.0–80.0% (62).
Metabolites
Sugimoto et al. (63) had studied 215 patients for salivary me-
tabolites using capillary electrophoresis time-of-flight mass
spectrometry (CE-TOF-MS). The cohort included oral cancer
patients (N = 69), pancreatic cancer patients (N = 18), breast
cancer patients (N = 30), periodontal disease patients (N = 11),
and healthy controls (N = 87). They identified 48 metabo-
lites for pancreatic cancer, of which eight metabolites (leucine
with isoleucine, tryptophan, valine, glutamic acid, phenylala-
nine, glutamine, and aspartic acid) were markers specific to
pancreatic cancer in the cohort.
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Exosomes
In 2010, it was found that saliva had proteins and functional
mRNA containing exosomes. These are cell specific lipid micro
vesicles (30–100 nm) that are able to migrate in the body pro-
moting intercellular communication. It has been suggested that
tumor-derived exosomes could function as the shuttle between
the distal tumor and the oral cavity leading to the develop-
ment of discriminatory salivary biomarkers.
Common commercial pathology laboratories
doing analysis of tissue
FoundationOne® (Cambridge, MA)
FoundationOne is a comprehensive genomic profile that applies
Next Generation Sequencing (NGS) to identify genomic al-
terations across genes known to be drivers of solid tumors.
They simultaneously sequence the coding region of 315 cancer
related genes including introns from 28 genes. Each reading
represents a unique DNA fragment to enable the highly sen-
sitive and specific detection of genomic alterations that
occur at low frequencies due to tumor heterogeneity, low tumor
purity, and small tissue samples. It detects all classes of
genomic alterations, including base substitutions, insertions,
deletions (indels), copy number alterations (CNAs), and re-
arrangements, using a small, routine FFPE sample (with core
or fine needle biopsies).
The test reporting is provided in an interpretive report both
in hard copy and via a web portal. The report identifies
the gene alterations and provides an interpretation that is
specific to the patient’s tumor (e.g. PDAC vs. gastric adeno-
carcinoma). It stresses on the more clinically relevant
alterations. In some cases, pertinent normal genes are also
reported. It also categorizes the variations into variants of
unknown significance, equivocal, and subclonal. Variants of
unknown significance (VUS) are deemed alterations de-
tected at their lab without any published characterization. It
is considered equivocal when there is some, not unambigu-
ous evidence of amplification or homozygous loss of a gene;
it is regarded as subclonal if the presence of the alteration
can be identified in less than 10% of the estimated tumor DNA.
At present, the genomic alteration list that FoundationOne
tests for includes: ABL1, ABL2, ACVR1B, AKT1, AKT2, AKT3,
ALK, AMER1(FAM123B), APC, AR, ARAF, ARFRP1, ARID1A,
ARID1B, ARID2, ASXL1, ATM, ATR, ATRX, AURKA, AURKB,
AXIN1, AXL, BAP1, BARD1, BCL2, BCL2L1, BCL2L2, BCOR,
BCORL1, BLM, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1,
BTK, C11 or f30(EMSY), CARD11, CBFB, CBL, CCND1,
CCND2, CCND3, CCNE1, CD274, CD79A, CD79B, CDC73Ê,
CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B,
CDKN2A, CDKN2B, CDKN2C, CEBPA, CHD2, CHD4, CHEK1,
CHEK2, CIC, CREBBP, CRKL, CRLF2, CSF1R, CTCF,
CTNNA1, CTNNB1, CUL3, CYLD, DAXX, DDR2, DICER1,
DNMT3A, DOT1L, EGFR, EP300, EPHA3, EPHA5, EPHA7,
EPHB1, ERBB2, ERBB3, ERBB4, ERG, ERRFI1, ESR1,
EZH2, FAM46C, FANCA, FANCC, FANCD2, FANCE, FANCF,
FANCG, FANCL, FAS, FAT1, FBXW7, FGF10, FGF14, FGF19,
FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR2, FGFR3, FGFR4,
FH, FLCN, FLT1, FLT1, FLT4, FOXL2, FOXP1, FRS2, FUBP1,
GABRA6, GATA1, GATA2, GATA3, GATA4, GATA6,
GID4(C17orf39), GLI1, GNA11, GNA13, GNAQ, GNAS,
GPR124, GRIN2A, GRM3, GSK3B, H3F3A, HGF, HNF1A,
HRAS, HSD3B1, HSP90AA1, IDH1, IDH2, IGF1R, IGF2,
IKBKE, IKZF1, IL7R, INHBA, INPP4B, IRF2, IRF4, IRS2, JAK1,
JAK2, JAK3, JUN, KAT6A(MYST3), KDM5A, KDM5C, KDM6A,
KDR, KEAP1, KEL, KIT, KLHL6, KMT2A(MLL), KMT2C(MLL3),
KMT2D(MLL2), KRAS, LMO1, LRP1B, LYN, LZTR1, MAGI2,
MAP2K1, MAP2K2, MAP2K4, MAP3K1, MCL1, MDM2, MDM4,
MED12, MEF2B, MEN1, MET, MITF, MLH1, MPL, MRE11A,
MSH2, MSH6, MTOR, MUTYH, MYC, MYCL(MYCL1), MYCN,
MYD88, NF1, NF2, NFE2L2, NFKBIA, NKX2-1, NOTCH1,
NOTCH2, NOTCH3, NPM1, NRAS, NSD1, NTRK1, NTRK2,
NTRK3, NUP93, PAK3, PALB2, PARK2, PAX5, PBRM1,
PDCD1LG2, PDGFRA, PDGFRB, PDK1, PIK3C2B, PIK3CA,
PIK3CB, PIK3CG, PIK3R1, PIK3R2, PLCG2, PMS2, POLD1,
POLE, PPP2R1A, PRDM1, PREX2, PRKAR1A, PRKCI,
PRKDC, PRSS8, PTCH1, PTEN, PTPN11, QKI, RAC1,
RAD50, RAD51, RAF1, RANBP2, RARA, RB1, RBM10, RET,
RICTORÊ, RNF43, ROS1, RPTOR, RUNX1, RUNX1T1,
SDHA, SDHB, SDHC, SDHD, SETD2, SF3B1, SLIT2, SMAD2,
SMAD3, SMAD4, SMARCA4, SMARCB1, SMO, SNCAIP,
SOCS1, SOX10, SOX2, SOX9, SPEN, SPOP, SPTA1, SRC,
STAG2, STAT3, STAT4, STK11, SUFU, SYK, TAF1, TBX3Ê,
TERCÊ, ÊTERT(promoter only), ÊTET2, TGFBR2, TNFAIP3,
TNFRSF14, TOP1, TOP2A, TP53, TSC1, TSC2, TSHR,
U2AF1, VEGFA, VHL, WISP3, WT1, XPO1, ZBTB2, ZNF217,
ZNF703.
The rearrangements searched for include:
ALK, BCL2, BCR, BRAF, BRCA1, BRCA2, BRD4, EGFR,
ETV1, ETV4, ETV5, ETV6, ETV6, FGFR2, FGFR3, KIT, MSH2,
MYB, MYC, NOTCH2, NTRK1, NTRK2, PDGFRA, RAF1,
RARA, RET, ROS1, TMPRSS2.
Guardant Health, Inc. (Redwood City, CA)
The Lab uses 10 mL blood to isolate and purify the cell-free
DNA (cfDNA). They then apply digital Next Generation Se-
quencing technology to identify genomic alterations in more
than 150,000 base-pairs across 70 oncogenes. They report
the amount of cfDNA mutant allele frequency (MAF) as a per-
centage as it relates to the germ line.
The lab reports a diagnostic accuracy of 97% with con-
current tumor tissue biopsies. In a study published in 2015,
they analyzed 54 genes in the tumors and cfDNA of 26 cancer
patients. Tumor sequencing failed in nine patients (35%). Of
the 31 mutations detected by tumor-biopsy NGS, 28 were also
detected by the cfDNA test (90.3% overlap with 95% CI).
KRAS, TP53, APC, SMAD4, GNAS, FBXW7, and BRAF were
the commonly mutated genes. On serial blood draws the di-
rection of change in tumor marker CA 19-9 and cfDNA-
percentage agreed significantly suggesting that cfDNA mutant
allele fraction changes reflect changes in disease burden over
time and treatment (48).
At present, the genomic alteration list that Guardant Health,
Inc. tests for includes:
a. 70 Point Mutations (SNVs) Genes: AKT1, ALK, APC, AR,
ARAF, AR1D1A, ATM, BRAF, BRCA1, BRCA2, CCND1,
CCND2, CCNEI, CDH1, CDK4, CDK6, CDKN2A, CDKN2B,
CTNNB1, EGFR, ERBB2, ESR1, EZH2, FBXW7, FGFR1,
FGFR2, FGFR3, GATA3, GNA11, GNAQ, G NAS, HNF1A,
HRAS, IDH1, IDH2, JAK2, JAK3, K IT, KRAS, MAP210,
MAP2K2, MET, MLH1, MPL, MYC, NF1, NFE2L2,
NOTCH1, NPM1, NRAS, NTRK1, PDGFRA, PIK3CA,
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PTEN, PTPNI1, RAF1, RB1, RET, RHEB, RHOA, R1T1,
ROS1, SMAD4, SMO, SRC, STK11, TERT, TP53, TSC1,
and VHL.
b. 18 CNV Genes: AR, BRAF, CCND1, CCND2, CCNE1,
CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, KIT, KRAS,
MET, MYC, PDGFRA, PIK3CA, RAF1.
c. 6 Fusion Genes: ALK, FGFR2, FGFR3, NTRK1, RET,
ROS1.
d. 3 Indel Genes: EGFR, ERBB2, MET.
Personal Genome Diagnostics (Baltimore, MD)
This company offers tissue and cfDNA analysis. For
tissue analysis it has three products: CancerSelect-88,
CancerSELECT-203 and CancerComplete. In CancerSelect-
88, 88 well-characterized cancer genetic alterations are
screened using Next Generation Sequencing to identify point
mutations, copy number alterations, and rearrangements. They
also do in-depth computational analyses, such as Digital Karyo-
typing, PARE, and other approaches.
The genetic alteration list that CancerSelect-88 tests for
includes:
a. sequence analysis for76 well-characterized cancer genes:
ABL1, ERBB4, GNAQ, MTOR, RET, AKT1, EZH2, GNAS,
NF1, ROS1, ALK, FANCA, HNF1A, NF2, SMAD4, APC,
FANCC, HRAS, NOTCH1, SMARCB1, ATM, FANCD2,
IDH1, NPM1, SMO, BRAF, FANCE, IDH2, NRAS, SRC,
BRCA1, FANCF, JAK2, NTRK1, STK11, BRCA2, FANCG,
JAK3, PALB2, TERT, BRIP1, FANCL, KDR, PDGFRA,
TP53, CDH1, FBXW7, KIT, PDGFRB, TSC1, CDKN2A,
FGFR1, KRAS, PIK3CA, TSC2, CSF1R, FGFR2, MET,
PMS2, VHL, CTNNB1, FGFR3, MLH1, PTCH1, DDR2,
FLT3, MPL, PTEN, EGFR, FOXL2, MSH2, PTPN11,
ERBB2, GNA11, MSH6 and RB1.
b. Copy number analyses for 13 well-characterized cancer
genes: ALK, ERBB3, FGFR3, MYC, RET, EGFR, FGFR1,
KIT, MYCN, ERBB2, FGFR2, MET and PDGFRA.
c. Rearrangement analyses for 14 well-characterized cancer
genes: ALK, EGFR, ETV6, PDGFRA, ROS1, BCL2, ETV1,
EWSR1, PDGFRB, TMPRSS2, BCR, ETV4, MLL and
RARA.
d. Microsatellite analyses, for five well-characterized cancer
genes: BAT-25, BAT-26, MONO-27, NR-21 and NR-24.
In CancerSELECT-203, 203 well-characterized cancer
genes are screened in both PDAC and normal samples. They
claim to be able to accommodate low abundance and poor
quality sample DNA. It also includes a high-quality inte-
grated analysis report.
The genes evaluated in CANCERSELECT-R™ 203 are:
a. Rearrangement analyses for selected regions of 24 well-
characterized cancer genes. ALK, EGFR, EWSR1,
PDGFRB, ROS1, BCL2, ETV1, MLL, PRKACA, TMPRSS2,
BCR, ETV4, MYC, RAF1, FGFR3, BRAF, ETV5, NTRK1,
RARA, TACC3, DNAJB1, ETV6, PDGFRA and RET.
b. Sequence and copy number analyses for the coding regions
of 195 well-characterized cancer genes: ABL1*, CBL*,
ERBB3*, FGFR2*, KDR*, ACVR1, CCND1*, ERBB4*,
FGFR3*, KIT*, AKT1*, CCNE1*, ERCC1, FGFR4*, KRAS*,
AKT2*, CDC73, ERCC2, FH, MAML1*, ALK*, CDH1,
ERCC3, FLCN, MAP2K1*, APC, CDK4*, ERCC4, FLT3*,
MAP2K4, AR*, CDK6*, ERCC5, FLT4, MDM2*, ARID1A,
CDKN1B, ESR1, FOXL2*, MDM4*, ARID1B, CDKN2A,
ETV1, GATA1, MED12*, ASXL1, CDKN2B, ETV5, GATA2*,
MEN1, ATM, CDKN2C, EWSR1, GNA11*, MET*, ATRX,
CEBPA, EXT1, GNAQ*, MLH1, AURKA, CHEK2, EXT2,
GNAS*, MLL*, AXIN2, CIC, EZH2*, GPC3, MPL*, BAP1,
CREBBP, FANCA, H3F3A*, MSH2, BCL2*, CSF1R*, FANCB,
H3F3B, MSH6, BCR, CTNNB1*, FANCC, HNF1A, MTOR,
BLM, CYLD, FANCD2, HRAS*, MUTYH, BMPR1A, DAXX,
FANCE, IDH1*, MYC*, BRAF*, DDB2, FANCF, IDH2*,
MYCL1*, BRCA1, DDR2, FANCG, IGF1R*, MYCN*, BRCA2,
DICER1, FANCI, IGF2R*, MYD88*, BRIP1, DNMT3A*,
FANCL, IKZF1, NBN, BTK, EGFR*, FANCM, JAK1*,
NCOA3*, BUB1B, EP300, FBXW7, JAK2*, NF1, CALR,
ERBB2*, FGFR1, JAK3*, NF2, NKX2-1*, PIK3CA*, RAD51C,
SF3B1*, TNFAIP3, NOTCH1*, PIK3R1, RAF1, SMAD2,
TOP1, NOTCH2*, PMS1, RB1, SMAD3, TP53, NOTCH3*,
PMS2, RECQL4, SMAD4, TSC1, NOTCH4*, POLD1, RET*,
SMARCB1, TSC2, NPM1, POLE, RNF43, SMO*, TSHR*,
NRAS*, POLH, ROS1, SRC, VHL, NTRK1, POT1, RUNX1*,
STAG2, WAS, PALB2, PRKAR1A, SBDS, STK11, WRN,
PAX5*, PRSS1, SDHAF2, SUFU, WT1, PBRM1, PTCH1,
SDHB, TERT, XPA, PDGFRA*, PTEN, SDHC, TET2, XPC,
PHOX2B, PTPN11*, SDHD, TGFBR2, XRCC1.
c. Microsatellite instability analyses for five markers: BAT-
25, BAT-26, NR-21, NR-24 and MONO-27.
In CancerComplete they utilize exome capture to selec-
tively analyze only the coding regions (exome) of the genome.
Additionally, the CancerSelect-88 panel genes are also ana-
lyzed, analyzing regions over >20,000 genes.
OncoPlex Diagnostics (now Nantomics) (Rockville, MD)
The company OncoPlex Diagnostics provides quantitative anal-
ysis of proteins and genomic targets in cancer diagnostics.
With the patented Liquid Tissue technology, coupled with mass
spectrometry and NGS, the OncoPlex Diagnostics test mea-
sures the amount of functional proteins and identifies genetic
mutations. Using laser microdissection, researchers are able
to isolate and sample only the tumor cells of interest, thereby
avoiding analysis of stroma. They also offer information on
treatment options that target the identified gene alteration, as
well as curated information enabling oncologists to aid on
patient management strategies.
The specimens required are usually Formalin-Fixed,
Paraffin-embedded (FFPE) tissue. Their standard protocol
entails one 5 µm H&E section and two or three 10 µm sec-
tions for laser microdissection.
Testing offered by OncoPlex Diagnostics includes:
a. Protein Expression Panel: ALK, AR, AXL, EGFR, ERCC1,
FGFR2, FR-α, hENT1, HER2, HER3, IGF1R, MET, MGMT,
MSLN, PD-L1, RON, ROS1, RRM1, SPARC, TOPO1,
TOPO2A and TUBb3.
b. Focus areas of the Protein Expression Panel (Chemother-
apy protein biomarkers): AR, ERCC1, FR-α, hENT1, MGMT,
RRM1, SPARC, TOPO1, TOPO2A, and TUBb3.
c. Protein biomarkers and targets by cancer type:
i. Breast cancer: AXL, EGFR, HER2, HER3, IGF1R,
MET, PD-L1, and ROS1.
ii. Gastrointestinal cancer: EGFR, FGFR2, HER2,
HER3, IGF1R, MET, MSLN, PD-L1, and RON.
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iii. Lung cancer: ALK, AXL, EGFR, HER2, HER3,
IGF1R, MET, MSLN,4 PD-L1, ROS1.
d. NSCLC differentiation: CK5, CK7, TP63, TTF-1.
e. Gene Mutation Panel: BRAF, EGFR, KRAS, NRAS, ABL1,
AKT1, ALK, APC, ATM, CDH1, CDKN2A, CSF1R, CTNNB1,
ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3,
FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, IDH2,
JAK2, JAK3, KDR, KIT, MET, MLH1, MPL, NOTCH1, NPM1,
PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4,
SMARCB1, SMO, SRC, STK11, TP53, and VHL.
f. Supplemental Testing Offered: HPV-infection associated
protein p16 (For head and neck cancers), ALK transloca-
tion by FISH (For NSCLC) and NSCLC differentiation: CK5,
CK7, TP63, and TTF-1.
Conclusion
In this post-genetic and data mining era with the availability
of rapidly advancing and varied levels of patient and tumor
data, academicians and clinicians are at a flexion point. The
surmounting data and inability to fully understand its capa-
bilities greatly humble even the best clinicians. As the data
gathering in multi-omic silos are being gradually structured and
paired with clinical data, researchers will be better equipped
to understand PDAC, and clinicians will be able to better
manage PDAC with more personalized care.
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